14 March 2003
Possibility to Treat Lung Tuberculosis without Use of Rifampicin in Heart Transplant Recipients – Two Cases ReportDariusz Jastrzebski, Michal Zakliczynski, Jerzy Kozielski, Miroslawa Siola, Szymon Dworniczak, Agnieszka Wojdyla, Marian Zembala
Ann Transplant 2003; 8(1): 42-44 :: ID: 496881
Pulmonary infections remain the leading cause of death in patients after heart transplantation. Lung tuberculosis is more common in transplant recipients than in general population. Two cases of tuberculosis are presented in patients after heart transplantation. Regarding to influence of rifampicin on immunosuppressive therapy, those patients were treated with antimycobacterial drugs except rifampicin. A cure without recurrence can be achieved with a scheme of treatment regimes without rifampicin.
Keywords: Heart Transplantation, Lung Tuberculosis Treatment
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review articleNormothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588